National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

66 -- WAVE NUCLEIC ACID FRAGMENT ANALYSIS SYSTEM SOL RFQ-NCI-00121 DUE 060200 POC Cynthia Brown, Purchasing Agent, 301-402-4509, Todd Cole, Contracting Officer The National Institutes of Health, National Cancer Institute (NCI), Laboratory of Population Genetics plans to procure a Wave Nucleic Acid Fragment Analysis System from Transgenomic, Inc., 5600 S 42nd Street, Omaha, NE 68107. The major focus of the Laboratory of Population Genetics is the identification of DNA sequence variations in human populations that may predispose individuals to diseases like cancer. The Laboratory recently began using a WAVE Nucleic Acid Fragment Analysis System to replace single-strand conformational polymorphism analysis, which has approximately 70% sensitivity for the analysis of the BRCA1 and BRCA2 genes. The experimental conditions for analysis have been optimized for the WAVE Nucleic Acid Fragment Analysis System and appears to have over 95" sensitivity in detecting mutations. The WAVE Neucleic Acid Fragment Analysis System is the only "complete" system having the necessary sensitivity that has a liquid chromatography apparatus, auto-sampler, oven, chromatography column, and software. The most important aspect, and other unique feature of the system, is the DNA Sep chromatography cartridge HPLC column with a propreitary matrix. The cartridge is formatted and optimized for the detection of sequence variation in double-stranded DNA on the system. The Transgenomic system includes a computer-controlled column oven with a range of 35-80 degree "C" and a precision of 0.1 degree "C" along with heating and cooling devices for temperature control of the separation buffers since temperature is an important parameter in the research. The Autosampler is formatted for 96-well trays, can be injected between 1 and 100 il of sample, temperature controlled from 4-60 degrees "C". The overall system is computer controlled and contains proprietary software to aid in using the system and analyzing the output data. In order to increase the number of samples we may analyze without introducing any additional experimental variables, such as different instruments with different characteristics, we planto purchase an additional WAVE Nucleic Acid Fragment Analysis System. Transgenomic Inc., is the only source known to the NCI Researcher that provides a "complete" instrument with high sensitivity that would not require the introduction of additional experimental variability into our analyses and has the sensitivity/features noted above. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements. Capability statements must be received in the contracting office by 2:00 pm, EST (local Washington time) on June 2, 2000. If you have any questions, please contact Cynthia Brown, Purchasing Agent, on (301) 402-4509. A determination by the Goverment not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered soley for the purpose of determining whether to conduct a competitive procurement. No collect calls of faxes will be accepted. Please refer to solicitation number RFQ-NCI-00121. Posted 05/15/00 (W-SN454756). (0136)

Loren Data Corp. http://www.ld.com (SYN# 0252 20000517\66-0002.SOL)